Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IBD

Incidence of HSV and HPV with azathioprine

Severe infections are an established risk of immunosuppressive therapy; however, the risk of opportunistic infections in patients with IBD who receive immunosuppressive therapy has so far only been studied retrospectively. The increased incidence of herpes flares and development or worsening of viral warts in patients with IBD who receive azathioprine has now been demonstrated for the first time in a prospective study.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Toruner, M. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134, 929–936 (2008).

    Article  Google Scholar 

  2. Lichtenstein, G. R. et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4, 621–630 (2006).

    Article  CAS  Google Scholar 

  3. Beaugerie, L. et al. The use of immunomodulators and biologics in inflammatory bowel diseases (IBD): a cross-sectional French nationwide cohort 2004–2005 [Abstract]. Gastroenterology 130 (4 Suppl. 2), A2 (2006).

    Google Scholar 

  4. Kane, S., Khatibi, B. & Reddy, D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am. J. Gastroenterol. 103, 631–636 (2008).

    Article  Google Scholar 

  5. Korelitz, B. I., Fuller, S. R., Warman, J. I. & Goldberg, M. D. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am. J. Gastroenterol. 94, 424–426 (1999).

    Article  CAS  Google Scholar 

  6. Gupta, G., Lautenbach, E. & Lewis, J. D. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4, 1483–1490 (2006).

    Article  Google Scholar 

  7. Seksik, P. et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment. Pharmacol. Ther. 29, 1106–1113 (2009).

    Article  CAS  Google Scholar 

  8. Spencer, E. S. & Andersen, H. K. Viral infections in renal allograft recipients treated with long-term immunosuppression. Br. Med. J. 2, 829–830 (1979).

    Article  CAS  Google Scholar 

  9. Warman, J. I., Korelitz, B. I., Fleisher, M. R. & Janardhanam, R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J. Clin. Gastroenterol. 37, 220–225 (2003).

    Article  CAS  Google Scholar 

  10. Viget, N., Vernier-Massouille, G., Salmon-Ceron, D., Yazdanpanah, Y. & Colombel, J. F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57, 549–558 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mario Cottone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cottone, M., Renna, S. Incidence of HSV and HPV with azathioprine. Nat Rev Gastroenterol Hepatol 6, 444–445 (2009). https://doi.org/10.1038/nrgastro.2009.110

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2009.110

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing